Navigation Links
2 immune-system proteins linked to colitis-associated cancer
Date:2/2/2009

Recent research from the laboratory of Michael Karin, PhD, at the University of California, San Diego School of Medicine the first researcher to demonstrate a molecular link between inflammation and cancer has identified two potential targets for the prevention and treatment of colitis-associated cancer (CAC), the most serious complication of inflammatory bowel disease.

Karin, Distinguished Professor of Pharmacology and Pathology and member of the Moores UCSD Cancer Center, and his team used genetic tools to demonstrate in mice that a cytokine called Interleukin 6 (IL-6), is an important regulator of tumor production during CAC development, and that its molecular effects are largely mediated by the transcription factor STAT3 in cancer cells. Their latest study which is also the first to establish the cancer-promoting function of STAT3 in a validated mouse model of human cancer will be published in the February 3 on-line edition of the journal Cancer Cell.

Recurrent inflammation and chronic infections contribute to a large number of different cancers including CAC which occurs in people suffering from chronic colitis, a common inflammatory bowel disease, putting them at very high risk for cancer. Cytokines small proteins released by immune-system cells have been suggested to drive early tumor growth by stimulating the growth and survival of pre-malignant cells.

In previous work, Karin's team showed that activation of a pro-inflammatory protein called NF-kB stimulates the proliferation of premalignant epithelial cells in CAC, giving rise to malignant growths in the colon. Interestingly, NF-kB in colonic epithelial cells promotes the development of cancer, not through inflammation, but through inhibition of apoptosis or cell death. On the other hand, NF-kB in the immune cells promotes cancer by enhancing inflammation, mostly by controlling the expression of pro-inflammatory cytokine expression. One of these cytokines was thought to be IL-6.

"IL-6 fosters chronic inflammation and malignant cell survival and growth by regulating the survival of T cells, white blood cells that direct the body's immune system," Karin said.

The proliferative and survival effects of IL-6 are largely mediated by the transcription factor STAT3, first suggested to have a cancer-promoting function by James Darnell at Rockefeller University in New York. The new work, which provides the first genetic evidence for the critical role of STAT3 in cancer using a mouse model of human cancer, also suggests that IL-6 and Stat3 constitute useful targets for the prevention and treatment of CAC, Karin added. The researchers showed that ablation of STAT3 in intestinal epithelial cells effectively inhibited CAC induction and growth in mice.

Colorectal cancer is one of the most common fatal malignancies worldwide, and almost half of all affected individuals die from the disease. Patients with inflammatory bowel disease, such as ulcerative colitis, are at a higher risk of developing colorectal cancer.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Preeclampsia May Stem From Malformed Proteins
2. Spinal fluid proteins signal Lou Gehrigs disease
3. 2 Cardiovascular Proteins Tied to Severity of Alzheimers
4. Two cardiovascular proteins pose a double whammy in Alzheimers
5. Stopping ovarian cancer by blocking proteins coded by notorious gene
6. Mutant proteins result in infectious prion disease in mice
7. Quintet of proteins forms new, early-warning blood test before heart attack strikes
8. Elaborate Network Drives When and Where Proteins Are Made
9. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
10. Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute
11. Discovery of key malaria proteins could mean sticky end for parasite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... AvePoint , ... North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East ... by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual ... the Diabetes Risk Test to find out if they are at risk for developing ... light up the evening sky by programming the LAX pylons the color red. Downtown’s ...
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... , ... The Thyroid Secret is a specialized 9-part documentary ... was recently launched on March 1, and Dr. Wentz discussed varied benefits and ... Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After being ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., ... to announce it has joined the National Association for Home Care and Hospice ... ill, disabled, and dying Americans of all ages and the caregiver who provide ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") ... financial results for the year ended December 31, ... 2017. The results are being released later than ... statements will include the operations and balances of ... 2016.  This release and filing date meets TSX ...
(Date:3/28/2017)... March 28, 2017 The global emerging cancer ... of 13.45% from 2016 to 2023 and reach a ... Cancer is a chronic disease and is affecting ... cancer diagnostics market. This report is focused on emerging ... market growth is propelled due to factors such as: ...
(Date:3/28/2017)... 2017 The U.S. Food and Drug ... adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is ... adequately by topical therapies, or those for whom ... used with or without topical corticosteroids. ... approving new and innovative therapies for patients with ...
Breaking Medicine Technology: